Resmed Inc’s recent filing unveils that its Officer Sandercock Brett acquired Company’s shares for reported $0.81 million on Sep 02 ’25. In the deal valued at $270.77 per share,3,000 shares were bought.
Then, Hernandez John sold 2,575 shares, generating $739,289 in total proceeds. Upon selling the shares at $287.10, the Director now owns 4,045 shares.
Before that, Hernandez John bought 2,575 shares. Resmed Inc shares valued at $739,289 were divested by the Director at a price of $287.10 per share.
CLSA upgraded its Resmed Inc [RMD] rating to an Outperform from a a Hold in a research note published recently. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who increased its forecast for the stock in mid July from “a Sector perform” to “an Outperform”. Morgan Stanley began covering RMD with “an Overweight” recommendation on March 19, 2025. Morgan Stanley started covering the stock on March 19, 2025. It rated RMD as “an Overweight”.
Price Performance Review of RMD
On Tuesday, Resmed Inc [NYSE:RMD] saw its stock fall -1.28% to $270.99. Over the last five days, the stock has lost -5.18%. Resmed Inc shares have risen nearly 11.66% since the year began. Nevertheless, the stocks have risen 18.50% over the past one year. While a 52-week high of $293.81 was reached on 08/22/25, a 52-week low of $199.92 was recorded on 04/07/25.
Levels Of Support And Resistance For RMD Stock
The 24-hour chart illustrates a support level at 268.76, which if violated will result in even more drops to 266.53. On the upside, there is a resistance level at 273.43. A further resistance level may holdings at 275.86.
How much short interest is there in Resmed Inc?
A steep rise in short interest was recorded in Resmed Inc stocks on 2025-08-15, dropping by -0.44 million shares to a total of 8.94 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 9.38 million shares. There was a decline of -4.92%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 16, 2025 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating.
